📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. (2022)

First Author: Jenkin D

Attributed to: UoOxford Confidence in Concept 2013 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2666-5247(22)00126-4

PubMed Identifier: 35907430

Publication URI: http://europepmc.org/abstract/MED/35907430

Type: Journal Article/Review

Volume: 3

Parent Publication: The Lancet. Microbe

Issue: 9

ISSN: 2666-5247